You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients

    SBC: PASCALL Systems, Incorporated            Topic: R

    PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

    SBC: REBISCAN, Inc.            Topic: N

    Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Treatment of diabetic retinopathy with TrkB agonist antibodies

    SBC: Zebra Biologics, Inc.            Topic: NEI

    Project Summary/AbstractDiabetic retinopathy (DR) is a major co-morbidity for patients with Type 1 and Type 2 diabetes. The incidence and severity of DR increase with duration of diabetes and approximately 30 percent will experience vision-threatening deficits. Work over the past decade has shown that the neural deficits observed in DR occur early in the natural history of the disease and likely p ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: ADK Group, LLC            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)

    SBC: Mulberry Biotherapeutics, Inc.            Topic: NINDS

    Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss

    SBC: Courage Therapeutics, Inc.            Topic: 300

    Rates of obesity have steadily increased in the United States, with approximately 50 percent of Americans projected to be classified as obese by 2030. Interestingly, obesity even seems to be a risk factor for the severity of illness in response to COVID-19 disease. Although behavioral (dieting and exercise), pharmacological, and surgical approaches exist for weight loss, many individuals who lose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A novel device for cervical insufficiency in pregnant women

    SBC: Cx Therapeutics, Inc            Topic: NICHD

    Abstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government